ArticleDiscover oncology2026
Association between serum chemerin and breast cancer mediated by lipid metabolism.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe association between chemerin and breast cancer is unclear. We aimed to clarify the association between serum chemerin levels and breast cancer risk in Chinese women, as well as the effects of lipid metabolism on this association.
methodsA 1:1 matched case-control study of 160 pairs was conducted using questionnaires to collect data on breast cancer risk factors. Serum chemerin levels were determined. Conditional logistic regression was used to analyze their association with breast cancer risk. A subgroup analysis of menopausal status was performed using unconditional logistic regression. The non-linear dose-response relationship was analyzed using restricted cubic splines. The effect of blood lipids on chemerin and breast cancer were explored using a mediating effect model.
resultsSerum chemerin levels of breast cancer patients were higher than those of controls in the overall group and menopausal subgroup. Taking the median of the control group as the cutoff value, women with higher chemerin levels had an increased odds of breast cancer compared to that of those with lower chemerin levels (for overall group: OR = 2.217, 95%CI: 1.125-4.367; for pre-menopausal group: OR = 4.713, 95%CI: 1.454-15.276; for post-menopausal group: OR = 2.103, 95%CI: 1.123-3.936). A linear dose-response relationship between serum chemerin levels and breast cancer odds was identified. The model showed that triglyceride (TG) statistically accounted for part of the association between chemerin and breast cancer (b = 0.034, P = 0.003), explaining approximately 15.0% of the total association.
conclusionsThere is a positive association between chemerin and breast cancer, which may be partly mediated by TG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.